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Background: Rituximab in the combination of CHOP chemotherapy has been widely used as the standard
treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL). Inactivation of phosphorylation of STAT3 plays
an essential role in rituximab-induced anti-proliferative activity in B-cell lymphoma. However, the relationship
between STAT3 genetic polymorphisms and clinical response to standard frontline treatment with rituximab has not
been well illustrated yet.
Methods: In this study we analyzed the STAT3 polymorphisms and prognosis of 166 diffuse large B-cell lymphoma
(DLBCL) patients who were treated with rituximab from 2007 to 2010. Determination of the STAT3 polymorphisms
of rs2293152 from genomic DNA was achieved by Sanger chain termination sequencing.
Results: We did not observe obvious correlation between patients’ disease features and STAT3 polymorphisms, but
patients with homozygous genotypes at rs2293162 showed a trend of higher CR rate than those with the
heterozygous genotype, especially in non-GCB subgroup (p = 0.011). Furthermore, homozygous genotypes GG and
CC also showed advantages of long-term survival compared with heterozygous genotype patients (p = 0.022).
Conclusions: These results suggest that STAT3 polymorphisms could be a suitable biomarker related to clinical
outcome of DLBCL patients treated with rituximab.
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Diffuse large B-cell lymphoma (DLBCL) is the most
common B-cell non-Hodgkin lymphoma (B-NHL) subtype
[1]. The introduction of rituximab plus cyclophosphamide/
doxorubicin/vincristine/prednisone (R-CHOP) chemo-
therapy is considered as the standard treatment for DLBCL
patients, which dramatically improves the treatment
outcome and prognosis [2]. However, a great number of
B-NHL patients treated with this immunotherapy still
develop primary and secondary resistance to rituximab
[3]. Thus, novel prognostic factors are being explored to
predict treatment outcome.* Correspondence: songyuqin622@sina.com; zhu-jun@bjcancer.org
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unless otherwise stated.STAT3 is a member of the signal transducer and activa-
tor of transcription (STAT) family, which regulates many
cellular and biological processes such as cell proliferation,
division, and apoptosis via mediation of related genes
expression [4,5]. Constitutively activated STAT3 has been
demonstrated to be essential for the proliferation and sur-
vival of DLBCL cells, which provides a prognostic indica-
tor and ideal target for DLBCL treatment [6,7]. Despite
the activation of antibody-dependent cellular cytotoxicity
(ADCC) and complement-dependent cytotoxicity (CDC),
many studies have demonstrated that rituximab could also
induce apoptosis by inhibiting phosphorylation of STAT3
in DLBCL cells [8,9]. We hypothesized that polymorphic
differences in STAT3 may account for distinct clinical effi-
cacy of rituximab in DLBCL patients.
In our study, initially several important single nucleotide
polymorphisms (SNPs) in STAT3 (including rs2293152,
rs6503695, and rs12949918), which have been associatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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alyzed in 166 peripheral blood specimens from DLBCL
patients treated with rituximab. During the following in-
vestigation of relationships between the polymorphisms
and clinical outcome, we eventually identified the prog-
nostic significance of STAT3 polymorphisms in rs2293152,




The general characteristics of the patients (82 male and
84 female patients) in this study are summarized in
Table 1. Sixty-three patients (38.0%) exhibited B symp-
toms. Eighty-eight patients (53.0%) were in stages 3 or 4,
and 50 patients (30.1%) had intermediate-to-high or high
international prognostic index (IPI) scores. Bone marrow
was involved by lymphoma in 5 patients (3.0%) at diag-
nosis. R-CHOP or R-CHOP like treatment as a frontline
regimen was administrated to 166 patients whose clin-
ical efficacy was evaluable for this study.
STAT3 polymorphisms
STAT3 polymorphisms at rs2293152 in 166 patients




CC + GG CG
Gender
Male 82 50 32 0.042
Female 84 38 46
Age
≤60 106 59 47 0.364
>60 60 29 31
B symptoms
Positive 63 31 32 0.442
Negative 103 57 46
LDH
Positive 78 39 39 0.464
Negative 88 49 39
β-2 MG
Positive 51 23 28 0.091
Negative 106 63 43
ESR
Positive 77 36 41 0.132
Negative 80 47 33
Stage
I-II 78 42 36 0.839
III-IV 88 46 42had homozygous CC genotype; 57 patients (34.3%), GG;
and 78 patients (47.0%), heterozygous CG. The frequency
of the C allele in DLBCL patients was 44.7%, and that of
the G allele was 55.3%. The genotype distribution of the
DLBCL population enrolled in our study was in Hardy-
Weinberg equilibrium with regard to the STAT3 polymor-
phisms examined.
Correlation analysis between STAT3 polymorphisms and
clinical features of DLBCL patients
Analysis of STAT3 polymorphisms of rs2293152 sug-
gested that patients with homozygous CC and GG geno-
types had a higher tendency to be male than those with
the heterozygous genotype (p = 0.042). Furthermore, our
data showed that an elevated β2-MG level might be less
frequent in patients with homozygous genotypes than in
those with the heterozygous CG genotype (p = 0.091).
The distribution of this STAT3 polymorphisms did not
correlate with the germinal center B cell-like (GCB) and
non-GCB subtypes (p = 0.229; Table 1).
Impact of the STAT3 polymorphisms on the curative
effect of rituximab
Of the 166 patients evaluable for response to R-CHOP




CC + GG CG
IPI score
0-2 116 61 55 0.867
3-5 50 27 23
Bulky mass
≥10 cm 33 19 14 0.557
<10 cm 133 69 64
Localized
Yes 27 17 10 0.258
No 139 71 68
Extra Nodal Site
≤1 123 64 59 0.669
>1 43 24 19
Incidence Site
Lymph node 95 46 49 0.170
Extra lymph 71 42 29
Ki-67
≤75 66 32 34 0.329
>75 85 48 37
Subtype
GCB 29 18 11 0.229
Non-GCB 113 56 57
Table 2 Genotype and allele frequencies of STAT3 polymorphisms in 166 Chinese patients with DLBCL
SNP Genotype frequencies
Genotype Freq Count Genotype Freq Count Genotype Freq Count Total
rs2293152 CC 0.187 31 CG 0.470 78 GG 0.343 57 166
SNP Allele frequencies
Allele Freq Count Allele Freq Count Total
rs2293152 C 0.447 109 G 0.553 135 244
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complete response (CR) rate of 52.4% (87 of 166 patients)
and a partial response (PR) rate of 33.7% (56 of 166 pa-
tients). As shown in Table 3, higher CR rate was observed
in patients with homozygous genotypes than in those with
the heterozygous CG genotype (p = 0.032). In subgroup
analysis based on the GCB/non-GCB molecular types,
patients with homozygous genotypes also showed better
CR rate than heterozygous genotype in non-GCB DLBCL
patients (p = 0.011).
Relationship between the STAT3 genotypes and time to
progression-free survival and overall survival
After a median follow-up time of 913 days (range, 60–
2591 days), 19 (11.4%) patients relapsed or progressed,
and 39 (23.5%) died. Six patients were enrolled in a
RAD001 maintenance therapy clinical study, and follow-
up data were not available for 12 patients. Therefore, a
total of 148 patients were evaluated for PFS and OS.
Patients with homozygous genotypes had a median PFS
of 909 days (range, 60–1851) versus 920 days (range, 78–
2591) for the heterozygous CG genotype patients, but theTable 3 Clinical response to rituximab according to
STAT3 polymorphism genotypes
Response Genotype p
CC + GG CG
All patients
CR 53(60.2) 34(43.6) 0.032
PR + PD + SD 35(39.8) 44(56.4)
OR 77(87.5) 66(84.6) 0.591
PD + SD 11(12.5) 12(15.4)
GCB subtype
CR 14(77.8) 8(72.7) 0.758
PR + PD + SD 4(22.2) 3(27.3)
OR 17(94.4) 11(100) 0.426
PD + SD 1(5.6) 0(0)
Non-GCB subtype
CR 32(57.1) 19(33.3) 0.011
PR + PD + SD 24(42.9) 38(66.7)
OR 46(82.1) 46(80.7) 0.844
PD + SD 10(17.9) 11(19.3)differences between these two groups did not reach
statistical significance (p = 0.227). Interestingly, a lon-
ger OR was observed in patients with homozygous ge-
notypes (range, 60–1851) compared with heterozygous
CG genotype patients (range, 170–2591; p = 0.022),
suggesting that STAT3 polymorphisms could be useful
markers to predict the long-term outcome of rituximab
treatment (Figure 1). However, this difference was not
observed when patients were subdivided into GCB and
non-GCB groups (data not shown).
In the multivariate analysis, we attempted to evaluate
the following variables on OS: stage, age, LDH level, β2-
microglobulin level, extranodal involvement, bulky mass,
IPI score, B symptoms, and STAT3 polymorphism. This
analysis also demonstrated that STAT3 polymorphism was
an important determinant of poor prognosis (p = 0.006;
HR 2.787; 95% CI 1.346-5.773; Table 4).
Discussion
In this retrospective analysis, STAT3 polymorphisms at
rs2293152 were found to associate with β2-MG levels
and patient sex. Patients with a CC and GG genotypes
at rs2293152 could benefit from rituximab-combined
chemotherapy.
Rituximab is a single human mouse chimeric IgG
antibody, which combines with the CD20 antigen on the
surface of DLBCL cells, directly killing these tumor cells
[12]. The antitumor activities of rituximab are mainly be-
lieved to be associated with the induction of ADCC and
CDC [13]. Polymorphisms in FcγRIIIa, which plays an es-
sential function in ADCC-induced lymphoma cell lysis,
were found to relate to the clinical response of rituximab
[14]. In a previous study, our group also demonstrated
that polymorphisms in the key CDC regulator, gene C1qA,
were related to the efficacy of rituximab in the treatment
of DLBCL patients [15]. Furthermore, rituximab has also
been suggested to induce apoptosis of lymphoma cells by
the inhibition of STAT3 phosphorylation. Various types of
tumor cells exhibited constitutively phosphorylated STAT3
within the nucleus, which has been shown to promote un-
controlled malignant tumor growth and relate with a poor
prognosis of patients [16,17]. However, the effect of STAT3
polymorphisms on the clinical antitumor activities of ri-
tuximab has not been reported before. In our study,
DLBCL patients with homozygous genotypes in STAT3
Table 4 Multivariate analysis of STAT3 polymorphisms on
survival
Variable Hazard ratio 95% CI p
IPI score 2.792 1.407 - 5.544 0.003
STAT3 polymorphisms 2.787 1.346 - 5.773 0.006
































Figure 1 Kaplan-Meier Curves for Progression-free Survival and
Overall Survival in DLBCL patients.
Hu et al. Cancer Cell International 2014, 14:25 Page 4 of 6
http://www.cancerci.com/content/14/1/25rs2293152 showed better CR rates. Furthermore, the im-
pact of STAT3 polymorphisms on the treatment efficacy
was also analyzed in GCB/non-GCB subgroups. Our results
showed that patients with homozygous genotypes also
showed higher CR rate than heterozygous genotype in non-
GCB DLBCL but not in GCB DLBCL subgroup, which was
consistent with previous reports that the activation of
STAT3 plays a more important role in ABC-DLBCL than
GCB-DLBCL [18,19]. On the other hand, the STAT3 poly-
morphism positions such as rs6503695 and rs12949918
did not show any such relationship with CR and OR rates
after rituximab treatment (data now shown).Previously STAT3 polymorphisms had been shown to
be suitable as predictive makers to analyze the response
to IFN-α in renal cell carcinoma [20]. In that study, the
SNP site within STAT3 resulted in a higher expression of
STAT3, which might contribute to resistance after IFN-α
treatment. The STAT3 SNP site rs2293152 C to G change
is an intronic polymorphism, which does not directly
introduce amino acid substitution. However, it is in-
creasingly being reported that intron SNPs and silent
polymorphisms could also alter the function of target
proteins [21,22]. Griseri et al. revealed that a synonymous
polymorphism within TTP was associated with protein
translation and clinical response rate to herceptin treat-
ment in breast cancer patients [23]. An ERCC1 poly-
morphism, which induced a codon change from common
usage codon AAC to AAT, has also been found to sup-
press ERCC1 expression, and the objective response rate
was much higher after oxaliplatin and 5-fluorouracil com-
bination chemotherapy in colorectal cancer patients [24].
In the previous analysis of rs2293152 locus of STAT3, Sato
et al. reported that the CC genotype was found to be asso-
ciated with the development of Clone Disease. The poly-
morphisms of STAT3 in rs2293152 may alter the function
of STAT3, further activating the inflammatory signaling
pathway and occurrence of the disease [25]. Thus, al-
though rs2293152 is a synonymous polymorphism, this
single nucleotide change might affect the phosphorylation
level of STAT3, which could contribute to influence the
curative effect of rituximab. However, further experi-
mentation is needed to explore the precise mechanism
by which STAT3 polymorphisms affect the lymphoma
responses to R-CHOP chemotherapy.
Conclusions
The STAT3 polymorphism could be a predictive bio-




A total of 166 consenting patients who received R-CHOP
or R-CHOP-like chemotherapy (R-COP, R-COPP and
R-CHOPE) as a frontline regimen between June 2007
and December 2010 were included in this retrospective
study from Peking University Cancer Hospital. All patients
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Organization classification, as confirmed by our Depart-
ment of Pathology. Peripheral blood specimens from all
lymphoma patients were obtained before the initiation
of therapy. R-CHOP chemotherapy was administered as
follows: one course of chemotherapy consisted of an
intravenous infusion of 750 mg/m2 cyclophosphamide,
50 mg/m2 adriamycin, and 2 mg vincristine, and oral ad-
ministration of 100 mg prednisone on days 1 to 5, which
was repeated every 3 weeks. Rituximab (375 mg/m2)
was infused for over 4–6 hours on day 1 before CHOP
or CHOP-like chemotherapy was started. The response
to R-CHOP therapy was evaluated after completion of
2–3 courses of therapy, 1–2 months after completion of
all planned therapy, and then every 3 months for the first
year and every 6 months thereafter until progression.
This retrospective research protocol was approved by
our Institutional Review Board.DNA extraction and genotyping
Genomic DNA was isolated from whole blood with the
Whole Blood Genome DNA Isolation Kit (Omega Bio-
Tek, Doraville, GA, USA) according to the manufacturer’s
instructions. DNA was diluted in water to a final stock
concentration of 30 ng/μl, and 1 μl was used in each PCR
reaction. Determination of STAT3 polymorphism geno-
types was achieved in a blinded manner on coded speci-
mens by Sanger chain termination sequencing. Briefly,
the genomic DNA region of interest was amplified using
rs2293152 forward primer 5′GGTCACCTACATAGTT
GATTG3′ and reverse primer 5′ACACCCCAGTTGTC
TTTCATC3′. An initial denaturation step at 94°C for 3
mins was followed by 35 cycles of denaturation at 94°C for
30 s, annealing at 56°C for 30 s, and extension at 72°C for
45 s. The final extension step was for 10 mins. The PCR
products were visualized on a 2% agarose gel. All frag-
ments were purified with the AxyPrep DNA Gel Ex-
traction kit (Axygen Sci. Inc., CA, USA). The purified
products were sequenced using an ABI 3730XL Avant
Genetic Analyzer (Applied Biosystems Inc., CA, USA).Definitions
Clinical responses were determined by physical examin-
ation and confirmed by computed tomography or ultrason-
ography. The latter was only used for evaluating superficial
lymph nodes. The responses were scored according to the
International Working Group criteria. Overall survival (OS)
was measured from day 1 of the first cycle of R-CHOP
until death from any cause or the last follow-up available.
The progression-free survival (PFS) was calculated from
day 1 of the first cycle of R-CHOP to disease progression
or death from any cause.Statistical analysis
The clinical characteristics and response rate of the pa-
tients were compared using chi-square and Fisher’s exact
tests. The Kaplan-Meier method was used to estimate
the differences of PFS and OS. The Cox regression
model was used to evaluate the prognostic factors. Dif-
ferences between groups were regarded as significant at
p < 0.05. SPSS16.0 was used for all statistical analysis.
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